Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
Authors:
- David J. KuterDKDavid J. Kuter
- Jiri MayerJMJiri Mayer
- Merlin EfraimMEMerlin Efraim
- Ross BakerRBRoss Baker
- Zane KaplanZKZane Kaplan
- Mamta GargMGMamta Garg
- Marek TrněnýMTMarek Trněný
- Philip Y. ChoiPCPhilip Y. Choi
- A. J. Gerard JansenAJA. J. Gerard Jansen
- Vickie McDonaldVMVickie McDonald
- Robert BirdRBRobert Bird
Open Access
- 29 March 2024
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (7) , 1715-1724
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease associated with autoantibody-mediated platelet destruction and impaired platelet production, resulting in thrombocytopenia and a predisposition to bleeding. The ongoing, global phase 1/2 study showed that rilzabrutinib, a Bruton tyrosine kinase inhibitor specifically developed to treat autoimmune disorders, could be an efficacious and well-tolerated treatment for ITP. Clinical activity, durability of response, and safety were evaluated in 16 responding patients who continued rilzabrutinib 400 mg twice daily in the long-term extension (LTE) study. At LTE entry, the median platelet count was 87 × 109/L in all patients, 68 × 109/L in those who had rilzabrutinib monotherapy (n = 5), and 156 × 109/L in patients who received concomitant ITP medication (thrombopoietin-receptor agonists and/or corticosteroids, n = 11). At a median duration of treatment of 478 days (range, 303-764), 11 of 16 patients (69%) continued to receive rilzabrutinib. A platelet count of ≥50 × 109/L was reported in 93% of patients for more than half of their monthly visits. The median percentage of LTE weeks with platelet counts ≥30 × 109/L and ≥50 × 109/L was 100% and 88%, respectively. Five patients discontinued concomitant ITP therapy and maintained median platelet counts of 106 × 109/L at 3 to 6 months after stopping concomitant ITP therapy. Adverse events related to treatment were grade 1 or 2 and transient, with no bleeding, thrombotic, or serious adverse events. With continued rilzabrutinib treatment in the LTE, platelet responses were durable and stable over time with no new safety signals. This trial is registered at www.clinicaltrials.gov as #NCT03395210 and www.clinicaltrialsregister.eu as EudraCT 2017-004012-19.Keywords
This publication has 37 references indexed in Scilit:
- Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)Journal of Medicinal Chemistry, 2022
- Psychometric properties of the EQ-5D-5L: a systematic review of the literatureQuality of Life Research, 2020
- Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for RomiplostimeClinicalMedicine, 2019
- New insights into the immune functions of complementNature Reviews Immunology, 2019
- Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial programAmerican Journal of Hematology, 2019
- Health‐related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of diseaseAmerican Journal of Hematology, 2016
- Prolonged and tunable residence time using reversible covalent kinase inhibitorsNature Chemical Biology, 2015
- Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value SetsValue in Health, 2012
- The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reportsAmerican Journal of Hematology, 2010
- T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpuraNature Medicine, 2003